Chhattisgarh HC: Infirmity in Cheque Return Memo Won’t Render Entire Trial u/s 138 of NI Act a Nullit  ||  Delhi HC: Lawyers have Great Responsibility towards Resolving Matrimonial Disputes  ||  Pat. HC: Mental Disorder for Divorce Must be Such that Spouse Can’t be Expected to Live with Other  ||  Delhi HC: Can Dispense Personal Hearing Only if Assessee's Rectification Application Is Allowed  ||  J&K HC: Fact that Civil Remedy is Available for Breach of Contract No Ground to Quash Cr. Proceeding  ||  SC: Cannot Grant Bail for Offence under Sec. 447 of Companies Act Without Fulfilling Twin Conditions  ||  Supreme Court: Can Pass Judgment on Admission Made Outside the Pleadings  ||  SC: All Proceedings Related to Land Allotment for Bom. HC's New Complex Must be Heard by Bombay HC  ||  NCLAT: No Requirement of Opportunity of Being Heard at Stage of Report Submission u/s 99 of IBC  ||  J&K High Court Notifies Video Conferencing (Nyaya Shruti) Rules, 2025    

Commerce Minister releases study report on Indian pharma exports to China- (Press Information Bureau) (18 Jun 2018)

MANU/PIBU/0962/2018

Commercial

For India to make a strong pitch for pharma exports to China, the Department of Commerce in coordination with Embassy of India at Beijing commissioned a study on "Enhancing Indian Exports of Pharmaceutical products to China" under the Market Access Initiative Scheme (MAI) to have a proper understanding of Chinese market and to help the Indian pharma industry to evolve appropriate and focused strategy for entry of the Indian generic drugs.

The study examines the health care market, pharmaceutical market the distribution system, procurement and bidding process and the regulatory landscape in China. The study also gives recommendations on how to access the Chinese market.

China' s health-care sector continues to grow rapidly with spending projected to grow from $ 357 billion in 2011 to $ 1 trillion in 2020. From pharmaceuticals to medical products to consumer health, China remains among the world's most attractive markets, and by far the fastest-growing of all the large emerging ones.

The study has been done by IMS Health team which worked with PHARMEXCIL and Industry stakeholders.

Tags : CHINA   PHARMA   EXPORT  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved